Posted inClinical Updates Gastroenterology Specialties
Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials
Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.